Open Access

Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet’s disease: a retrospective observational study

  • Yohei Kirino1, 11Email authorView ORCID ID profile,
  • Haruko Ideguchi2, 11,
  • Mitsuhiro Takeno3, 11,
  • Akiko Suda4, 11,
  • Kana Higashitani1,
  • Yosuke Kunishita1, 11,
  • Kaoru Takase-Minegishi5, 11,
  • Maasa Tamura1, 11,
  • Toshiyuki Watanabe6, 11,
  • Yukiko Asami1, 11,
  • Takeaki Uehara7, 11,
  • Ryusuke Yoshimi1, 11,
  • Tetsu Yamazaki8, 11,
  • Akiko Sekiguchi9, 11,
  • Atsushi Ihata6, 11,
  • Shigeru Ohno5, 11,
  • Atsuhisa Ueda1, 11,
  • Toshihisa Igarashi8, 11,
  • Shohei Nagaoka2, 11,
  • Yoshiaki Ishigatsubo10, 11 and
  • Hideaki Nakajima1
Arthritis Research & Therapy201618:217

https://doi.org/10.1186/s13075-016-1115-x

Received: 6 July 2016

Accepted: 8 September 2016

Published: 3 October 2016

Abstract

Background

It has been suggested that the phenotypes of Behçet’s disease (BD) in Japan are changing. To ask whether the evolution of BD holds true in recent-onset cases in Japan, we performed a retrospective study.

Methods

We reviewed the records of 578 patients with BD who met the 1987 revised diagnostic criteria of the Behçet’s disease research committee of Japan. The patients were divided into three groups based on the date of disease onset. We compared the demography, clinical features, and treatments among them with or without adjustment for the observation period. Patients having oral ulcers, genital ulcers, regional skin involvement, and uveitis are categorized as having complete-type BD, and the associated factors were determined by univariate and multivariate logistic regression analyses.

Results

Male patients had a higher propensity for uveitis and central nervous system (CNS) involvement, whereas female patients had higher rates of genital ulcers and arthritis. We found a significant trend in reduction of complete-type, genital ulcer, HLA-B51 carriers, and increment of gastrointestinal BD over time. Multiple regression analysis identified HLA-B51 positivity, earlier date of disease onset, and younger age of onset as independently associated with complete-type BD. Although treatments had been also chronologically changed, the causative relationship between therapeutic agents and phenotypical changes was not determined from the study.

Conclusion

The present study revealed that phenotypical evolution was characterized by decreased incidence of the complete type and increment of gastrointestinal involvement in Japanese patients with BD during the last 30 years.

Keywords

Behçet’s disease Evolution HLA-B51 Complete type

Background

Behçet’s disease (BD) is an inflammatory disease of unknown cause, affecting multiple organs such as eyes, skin, mucosa, and brain [1]. A definitive environmental factor associated with BD is still unknown. Microbes such as Streptococcus sanguinis and herpes simplex have been implicated in BD pathogenesis [2, 3], and genetic evidence supporting association with microbiomes in the development of BD is growing [4]. Moreover, dysbiosis in the intestinal flora has been reported in many inflammatory diseases including BD [5, 6]. It is thus possible that environmental factors modify the clinical courses and phenotypes of BD.

Epidemiological studies from Japan and Korea have shown that the prevalence of BD, particularly of patients with serious manifestations, is decreasing [79]. We previously reported that newly diagnosed complete-type BD (patients having all four of the major symptoms of oral ulcers, genital ulcers, and eye and skin lesions) in Kanagawa district, Japan had been declining since the year 2000, compared with the previous data (33 % of patients diagnosed before 2000 had complete BD compared to 23 % of patients between 2000 and 2007) [8]. Similarly, a recent paper from Korea also reported reduction in the complete type, declining male propensity, and shifting patterns of organ involvement, during the last 30 years [9]. However, to our knowledge, such chronological changes in the BD phenotype have been reported only in Japan and Korea, where the majority of the residents have been native and genetically homogenous, with infrequent influx of immigrants from other ethnic groups. These findings suggest the involvement of altered environmental factors in the phenotypical changes in BD in these countries. To determine whether the trends were transient or continuous in the same area, this study enrolled patients newly diagnosed with BD after 2008 and compared them with the previous cohorts reported by Ideguchi et al [8].

Methods

The patients who participated in the study met the 1987 revised diagnostic criteria of the Behçet’s disease research committee, the Ministry of Health, Labor and Welfare of Japan [10]. These patients had been treated in any of the seven hospitals within the Kanagawa district located in mid-Japan, from July 1991 to December 2015. All patients were Japanese except for four patients (one Filipino, one Syrian, one Korean, and one Chinese patient). The study was approved by the Ethic Committee of Yokohama City University (A141127010). The study followed the Ethical Guidelines for Epidemiology Research, published by the Japanese Ministry of Health, Labor, and Welfare, applying the opt-out strategy. In addition to patients who participated in the study reported by Ideguchi, we extracted all of the patients with a diagnosis of BD from the computerized medical records in the seven participating hospitals. Thereafter, different rheumatologists (YK Kirino, HK, AS Suda, Y Kunishita, KM, TM, TW, YA, TU, RY, TY, and AS Sekiguchi) reviewed the records for their clinical manifestations and treatment regimens.

Under the Japanese criteria, recurrent aphthous oral ulcers, skin lesions, ocular inflammation, and genital ulcers are included in “major symptoms”, whereas arthritis, intestinal ulcers, epididymitis, vascular lesions, and neuropsychiatric disease are included under “minor symptoms”. The criteria classify clinical subtypes into complete and incomplete types. The former includes patients with all four major symptoms during the clinical course, whereas the latter includes those having three major symptoms, two major and wo minor symptoms, typical recurrent ocular inflammation and one or more major symptoms, or typical recurrent ocular inflammation and two minor symptoms. Moreover, patients with central nervous system (CNS) involvement, vascular, and gastrointestinal (GI) region involvement were categorized as having special-type BD, and were further defined as the neurologic type, vascular type, and GI type, respectively.

To reduce the heterogeneity of patients with BD and to be comparable with other BD studies, we also applied International Study Group (ISG) criteria to our patients [11]. We extracted the following variables from the patients’ records; BD phenotype, sex, age of BD onset, date of disease onset, HLA-B51 positivity, observation period, and treatment with biologic agents.

Statistical analysis

Statistical analysis was performed with GraphPad Prism 6 (San Diego, CA, USA) and SPSS version 22 (IBM Japan, Tokyo, Japan). Categorical variables were analyzed using the chi-square test or Cochran–Armitage test. Continuous variables were analyzed using the Student t test. Univariate and forward stepwise multivariate logistic regression analysis was performed with presence of complete-type BD as the dependent variable. Sex and age of BD onset were forced into into the model. Variables that were significant in univariate analysis were further included in the multivariate analysis. A p value less than 0.05 was considered as statistically significant.

Results

We first carefully examined patients’ records and identified 578 patients who met the 1987 revised Japanese BD diagnostic criteria, including 412 patients reported in the previous paper [8] (Fig. 1). The clinical characteristics are shown in Table 1. Consistent with our previous data [8], genital ulcers and arthritis were more frequent in female patients, whereas eye disease and CNS involvement were more common in male patients. There was no difference in HLA-B51 positivity between male and female patients: both had higher HLA-B51 positivity than the general Japanese population (about 15 %), indicating that the estimated odds ratio of HLA-B51 positivity in BD was approximately 3.5 in this series.
Fig. 1

Scheme of the patients with Behçet’s disease who participated in the study

Table 1

Characteristic of patients with Behçet’s disease (BD) who were enrolled in the study

Characteristics

All (n = 578)

Male (n = 247)

Female (n = 331)

P a

Age at onset (mean ± SD)

36.8 ± 12.4

35.2 ± 12.1

37.8 ± 12.0

0.013 b

Observation period (mean ± SD)

9.2 ± 9.2

8.2 ± 7.6

9.6 ± 8.4

0.036 b

HLA-B51, n (%)

177/352 (50.3)

88/170 (51.8)

89/182 (48.9)

0.59

Oral ulcer, n (%)

572 (99.0)

246 (99.6)

326 (98.5)

0.11

Genital ulcer, n (%)

417 (72.3)

141 (57.3)

276 (83.4)

<0.0001

Eye involvement, n (%)

356 (61.6)

181 (73.3)

175 (52.9)

<0.0001

Skin involvement, n (%)

513 (88.8)

212 (85.8)

301 (90.9)

0.055

Arthritis, n (%)

301 (52.1)

104 (42.1)

197 (59.5)

<0.0001

Epididymitis, n (%)

14 (2.4)

14 (5.7)

  

Gastrointestinal involvement, n (%)

71(12.3)

26 (10.5)

45 (13.6)

0.069

CNS involvement, n (%)

59 (10.2)

34 (13.8)

25 (7.6)

0.015

Vascular involvement, n (%)

46 (8.0)

25 (10.1)

21 (6.3)

0.097

Fulfilling ISG, n (%)

517 (89.4)

213 (86.2)

304 (91.8)

0.030

aMale vs. female groups. bAnalyzed using the unpaired t test. Other variables were analyzed using the chi-square test. CNS central nervous system, ISG International Study Group criteria for BD. Significant results are highlighted in bold font

As mentioned earlier, we had divided the patients into two groups of patients diagnosed before 2000 and those diagnosed between 2000 and 2007, in the previous paper [8]. Therefore, in the current study, the patients were divided into three groups; group A (before year 2000), group B (between 2000 and 2007), and group C (after 2008, after the publication by Ideguchi), according to the date of BD diagnosis (Table 2). In the previous study there were significant reductions in the frequency of the complete type, of genital ulcers, skin involvement, and CNS involvement in group B compared to group A [8]. As shown in Table 2 we confirmed that these trends were continuous after 2008. However, there was also significant differences in the observation period among the three groups.
Table 2

Evolution of clinical phenotypes of Behçet’s disease in Japan before correction for the follow-up period

 

Group A pre 2000 (n = 323)

Group B 2000–2007 (n = 164)

Group C Post 2008 (n = 91)

P

Observation time (years)

11.9 ± 9.3

6.3 ± 4.8

3.7 ± 2.2

<0.0001

Age at onset

36.9 ± 11.8

35.8 ± 13.1

37.6 ± 11.4

NS

Gender male, n (%)

134 (41.5)

76 (46.3)

37 (40.7)

0.80

HLA-B51, n (%)

107 (54.9)

48 (49.0)

16 (43.1)

0.061a

Complete type, n (%)

124 (38.4)

45 (27.4)

16 (17.6)

<0.0001

Oral ulcer, n (%)

321 (99.4)

163 (99.4)

88 (96.7)

0.065

Genital ulcer, n (%)

246 (76.2)

116 (70.7)

55 (60.4)

0.0033

Eye involvement, n (%)

211 (65.3)

92 (56.1)

53 (58.2)

0.083

Skin involvement, n (%)

293 (90.7)

145 (88.4)

75 (82.4)

0.033

Arthritis, n (%)

166 (51.4)

87 (53.0)

48 (52.7)

0.75

Gastrointestinal involvement, n (%)

37 (11.5)

20 (12.2)

14 (16.5)

0.35

CNS involvement, n (%)

39 (12.1)

17 (10.4)

3 (3.3)

0.023

Vascular involvement, n (%)

26 (8.1)

17 (10.4)

3 (3.3)

0.35

aNot all of the patients were typed for HLA-B51 positivity. Significant results are highlighted in bold font. CNS central nervous system, NS not significant

In our previous study the clinical picture was of BD evolving even after achieving the definitive diagnosis and of patients with a longer history of BD presenting with more manifestations [8]. Thus, we next adjusted the observation duration among the three groups by selecting symptoms appearing within 4.5 years after the onset of disease. Patients without data on the onset of individual manifestations were excluded from the analysis (Table 3). Even after the adjustment, the date-dependent reduction in the complete-type BD and genital ulcers remained statistically significant. In addition, there was a reduced rate of HLA-B51 positivity and increased rate of the GI type. There were no significant shifts in the rate of male patients or age of disease onset, which are predisposing factors to the severe BD phenotype [12, 13]. Although the frequency of genital ulcers was significantly reduced in female patients (p = 0.025 compared p = 0.13 for male patients), this symptom was still more common in female than in male patients.
Table 3

Evolution of clinical phenotypes of Behçet’s disease in Japan after correction for the follow-up period

 

Group A Pre 2000 (n = 293)

Group B 2000–2007 (n = 160)

Group C Post 2008 (n = 91)

P

Observation time (years)

3.52 ± 1.6

3.25 ± 1.7

3.7 ± 2.2

NS

Age at onset

36.4 ± 11.9

35.8 ± 13.0

37.6 ± 11.4

NS

Gender male, n (%)

121 (41.3)

74 (46.3)

37 (40.7)

0.81

HLA-B51, n (%)

103 (53.4)

47 (50.0)

16 (43.1)

0.031 a

Complete type, n (%)

99 (33.8)

37 (23.1)

16 (17.6)

0.0008

Oral ulcer, n (%)

291 (99.3)

159 (99.4)

88 (96.7)

0.079

Genital ulcer, n (%)

219 (74.7)

112 (70.0)

55 (60.4)

0.0096

Eye involvement, n (%)

184 (62.8)

85 (53.1)

53 (58.2)

0.19

Skin involvement, n (%)

255 (87.0)

137 (85.6)

75 (82.4)

0.28

GI, n (%)

18 (6.1)

19 (11.9)

14 (16.5)

0.0036

CNS, n (%)

20 (6.8)

14 (8.8)

3 (3.3)

0.46

Vascular, n (%)

17 (5.8)

15 (9.4)

3 (3.3)

0.73

Complete type fulfilling, n ISG (%)

99/264 (37.5)

37/135 (27.4)

16/74 (21.6)

0.0037

Complete type w/o GI, n (%)

96/275 (34.9)

35/141 (24.8)

15/77 (19.5)

0.0030

Numbers of patients shown are different from Table 2 because 31 patients were excluded due to ambiguity of the date of phenotype expression. aNot all of the patients were typed for HLA-B51 positivity. GI gastrointestinal, CNS central nervous system, w/o without, NS not significant

All patients met the Japanese criteria in this study, but 61 patients (10.6 %) did not meet the ISG criteria (Table 1). On the other hand, patients fulfilling the ISG criteria but not the Japanese criteria were not enrolled found in our cohort, because the ISG criteria list only four symptoms besides a positive pathergy test, and phenotypical diversity is more restricted than in the Japanese criteria. The frequency of complete-type BD was chronologically reduced or limited in patients fulfilling the ISG criteria (Table 3).

The frequency of patients with the GI type of BD have been recently increasing. We and others have shown that these patients have a lower frequency of HLA-B51 positivity, complete-type disease, and uveitis [14, 15], suggesting that the GI type might have unique genetic and phenotypical features in comparison with patients who have other subtypes of BD [16] (Additional file 1: Table S1). To examine whether recruitment of more patients with GI type BD in group C could result in a reduction in the rate of complete-type BD, we looked at the rates of the complete type in patients without GI involvement. Even after excluding these patients, there was a significant reduction in the complete type (Table 3).

A meta-analysis has shown that HLA-B51 is associated with male predominance and moderately higher prevalence of genital ulcers, skin involvement, ocular involvement, and decreased prevalence of GI involvement [14]. Therefore, a reduced rate of HLA-B51-positive patients in our cohort could be implicated in the increased frequency of the milder disease phenotype. However, our data revealed that the phenotypical evolution was found in HLA-B51-positive patients as well as in other patients (the rate of the complete type in HLA-B51-positive cases was 46.6 % before 2000, 29.8 % in 2000–2007, and 31.8 % in 2008–2015), though the sample size was presumably too small (n = 172) to obtain a statistically significant result (p = 0.062).

In the current study, patients were arbitrarily segmented into three groups based on disease onset, which may have resulted in skewed outcomes. In addition, multiple factors mutually contribute to the reduced rates of complete-type BD. To identify factors independently associated with complete-type BD, we performed univariate and multivariate logistic regression analyses, with the complete type as a dependent variable. In multivariate analysis, young age of onset, HLA-B51 positivity, and earlier date of diagnosis were independently associated with risk of developing complete-type BD (Table 4).
Table 4

Univariate and multivariate logistic regression analysis with the complete type as a dependent variable

 

Univariate

Multivariate

P

Odds ratio

95 % CI

P

Odds ratio

95 % CI

Age of onset

0.024

0.98

0.97

1.00

0.049

0.98

0.96

1.00

Sex

0.275

0.82

0.58

1.17

0.26

0.77

0.49

1.22

Date of onset

1.1 × 10 -5

0.37

0.24

0.58

0.02

0.50

0.28

0.90

Gastrointestinal

0.01

0.44

0.23

0.82

    

Central nervous system

0.038

1.78

1.03

3.08

    

Vascular

0.37

0.73

0.37

1.45

    

HLA-B51

5.4 × 10 -4

2.21

1.41

3.46

4.5 × 10 -4

2.27

1.44

3.59

Forward stepwise logistic regression analysis was performed. Gastrointestinal, central nervous system, and vascular Behçet’s disease were not selected in the multivariate model

Change of treatment strategies, especially use of biologic agents, during the last two decades could have profound effects on the phenotypes of BD, as azathioprine has been suggested to modify the natural clinical course [17]. In Japan, the approval of infliximab (IFX) for uveitis in 2007, and adalimumab (ADA) for the GI type in 2013, have encouraged us to introduce biologic agents as early as possible in serious cases. Early initiation of biologic agents could suppress the appearance of additional symptoms, leading to phenotypical changes in recently enrolled patients in our cohort. We asked whether patients with IFX or ADA had different phenotypes among groups A, B, and C, but there were no significant differences among the groups in the rates of patients with the complete or GI type who were receiving TNF inhibitors, in spite of the increasing number of users (Additional file 2: Table S2). Patients who required anti-TNF therapy had already been found to have a mature BD phenotype at the start of therapy.

It is also possible that earlier detection of BD may lead to early intervention, resulting in a milder disease phenotype. However, there was no difference among the groups in the age of disease onset. Moreover, we have collected data on the use of prednisolone, colchicine, azathioprine, calcineurin inhibitors, methotrexate, and non-steroidal anti-inflammatory drugs (NSAIDs) in 456 patients for whom treatment data were available. As shown in Additional file 3: Table S3, we found that use of calcineurin inhibitors was decreased, while other drugs were increased. The results suggest that change of treatment strategy could have affected the BD phenotype in our patients. These data collectively indicate that the phenotype of BD is evolving in patients with recent onset of BD in our district.

Discussion

In the present study, we observed a continuous reduction in complete-type BD in our district since the previous report in 2007 [8]. Moreover, we a reduced rate of genital ulcers, reduction in HLA-B51-positive patients, and increased prevalence of the GI type have persisted. Of these, HLA-B51 was found to be associated with the complete type in multivariate analysis. Therefore, it is likely that the decreased proportion of HLA-B51-positive patients is partially responsible for the recent phenotypical change, though a trend towards decline in the complete type was also observed in HLA-B51-positive patients. Although increment of the GI type, which was negatively associated with the complete type, was one of the important consequences in this study, it did not directly result in reduction in the complete type in our analysis. Of note, the analysis confirmed that the complete type was associated with an earlier date of BD onset. A similar evolution of the BD phenotype has been reported, not only in the Yokohama area, but also in other parts of Japan [7, 18], and recently in Korea [9]. Please change the ref3 to ref9 These data suggest that change in the BD phenotype is ongoing in East Asia.

The reduction in HLA-B51-positive BD patients in our cohort is intriguing. This phenomenon is difficult to explain, because the pathogenic role of HLA-B51 in the development of BD is not fully understood. Rather, our data suggest that interaction between HLA-B51-restricted immune responses and external factors is involved in the disease process, and that altered environmental factors attenuate the immune responses, resulting in reduced prevalence and phenotypical changes to mild forms in HLA-B51-positive individuals. Besides detailed molecular analysis, clinical observations as in this study may also contribute to understanding the pathogenesis of BD.

Several lines of evidence suggest that both genetic and environmental factors are involved in the pathogenesis of BD. An epidemiological study of immigration supports the hypothesis that BD has a primarily hereditary basis [19], while others report a significant impact of environmental factors, including life style, on disease development [20, 21]. Ethnic and regional differences in the clinical phenotypes of BD also suggest genetic factors are implicated in the clinical course after disease onset [22]. However, genetic backgrounds were highly preserved in a series of the cohort studies, because we have evaluated mostly Japanese patients. This was the case for other studies in Japan and Korea. Thus, it is likely that environmental factors contribute more to the phenotypical changes of BD in this area than genetic factors.

As for environmental factors, microbial pathogens are implicated in the development of BD [23]. Previously, we raised the possibility that improved oral hygiene contributes to the suppression of microbial pathogen-related immune responses [8]. It has long been suggested that microorganisms such as Streptococcus sanguinis provoke inflammation in BD [2, 2325]. Smoking and gingivitis have been shown to be environmental factors, which potentially affect the components of oral flora [26]. Interestingly, both factors are also identified as predisposing factors in the development of rheumatoid arthritis through the generation of citrullinated peptides as autoantigens [27], though it seems unlikely that the same molecular mechanism operates in BD. Unfortunately, details of smoking were unavailable in this study.

BD flares are often caused by bacterial infection and after dental care, also suggesting oral flora involvement in the BD process [28, 29]. Moreover, our recent genetic association study implicated innate immune receptors involved in detecting microorganisms in the development of BD [4]. It is possible that change in environmental factors, such as resident microbial components, are altering functions of BD-susceptibility genes. However, which microorganisms, if any, are responsible for inflammation or reduction in the complete type in BD is unknown, and there is no evidence showing such microbiome structural alteration is actually occurring in Japan.

The present study showed that the factor most strongly attributing to reduction in complete type BD was genital ulcers, especially in female patients. Because it is likely that the decrease in prevalence of genital ulcers is caused by environmental factors, identification of the causative factors would give us a good clue in understanding the pathogenesis of BD.

The ISG criteria are one of the most commonly applied in BD studies [11]. The ISG criteria and the Japanese criteria use different sets of clinical information; the ISG criteria do not include clinical manifestations, which are listed as special types in the Japanese criteria, whereas the pathergy test is not included in the Japanese criteria. In spite of the discrepancy, the two previous independent genome-wide association studies (GWAS) have identified similar genetic architecture between Turkish BD (diagnosed using the ISG criteria) and Japanese BD (diagnosed using the Japanese criteria), suggesting that patients diagnosed with the two different sets of criteria are comparable [30, 31]. Indeed, the major conclusions of this study are not altered or limited in patients fulfilling the ISG criteria.

Consistent with previous studies, we found that the GI type was the only manifestation that increased among the serious phenotypes. The most apparent difference between the Japanese criteria and the ISG criteria lies in the presence of the GI type. Our previous paper reported that Japanese patients with GI-type BD fulfilled the ISG criteria at a lower rate compared with those with the non-GI type (with the GI type 70 % vs. 92 % without the GI type) [16]. It is still under consideration as to how to classify the GI type BD in patients who have a typical deep ulcer in the ileocecal region, but do not fulfill the ISG criteria. Our data suggest that due to increment of the GI type in East Asia, such patients should be followed carefully, as extensively discussed in a report from Korea [32].

It has long been recognized that the incidence of inflammatory bowel disease (IBD) such as Crohn’s disease is rising in many countries, and may be attributed to change to a high-fat diet [33]. In Japan, the prevalence of Crohn’s disease increased from 2.9 per 100,000 persons in 1986 to 63.6 in 2005 [34]. Similar mechanisms might be involved in the increased incidence of the GI type of BD. Indeed, IL23R and IL10 have been identified in GWAS of BD [30], which are well-established IBD loci, supporting the notion that common mechanisms play roles in the development of GI-type BD.

Increment of GI involvement was associated with increased use of NSAIDs, suggesting that NSAIDs may be a risk factor for GI involvement in BD and in IBD. However, as significant association has been identified between GI involvement and arthritis [16], NSAIDs might be more frequently used in patients with GI-type BD because of complicated arthritis. Thus, it is hard to make conclusions about the cause-effect relationship between NSAIDs and GI involvement in the present study.

In our cohort, chronological changes in therapy could have affected the phenotypes and clinical course of disease. However, care should be taken to interpret the data because of possible bias caused by incomplete data collection, particularly in the early days. Moreover, the clinical diversity of BD makes it difficult to assess the disease-modifying effect of each therapeutic agent. It is hard to determine whether a particular symptom does not appear as a natural course or whether it has been suppressed by the preceding therapy. Moreover, because most treatments were determined by the attending physicians, the therapeutic scenario was not consistent in patients having a particular symptom, even on the same date.

Although we were unable to show significant effects of biologic treatment on the evolution of the BD phenotype, it is possible that immunosuppressive treatment prevented subsequent development of the complete-type and special-type BD. In a placebo-controlled trial of azathioprine, vascular involvement developed more frequently in the placebo group [17]. In addition, a case of vascular BD after termination of IFX was reported [35]. However, in the current study, we did not observe a significant reduction in eye disease, vascular type, or CNS involvement in BD; rather, there was increment of GI BD (Table 3). Patients with eye disease and special-type BD often require intensive immunosuppressive treatments, but not for genital ulcers (usually treated by topical or oral steroids). Because genital ulcers usually precede special-type manifestations [8], it is unlikely that recent therapeutic changes caused a reduction in genital ulcers during recent decades. However, due to the retrospective nature of our study, we cannot exclude the possibility of treatment effect on the evolution of the BD phenotype. To address the question, future prospective studies with larger sample size and longer observation period are needed.

There are several limitations in the study. First, the data were retrospectively collected, therefore were subject to selection bias. Second, data on important epidemiological factors such as smoking status, changes in diet, and body mass index were not available in all the patients. Third, because treatments were principally determined by the individual attending physicians and were not necessarily consistent among the patients, it was hard to assess the influence of therapeutic regimens on disease manifestations.

Conclusions

Our cohort study showed that a reduced rate of complete-type and increased rate of GI-type BD are continuous trends in East Asia. Because the genetic background was consistently homogeneous in our study population, it is likely that the time-dependent changes were caused by environmental factors. Identification of causative factors would give a clue in the establishment of novel strategies to modify the clinical course and suppress disease flares as prophylactic medicine.

Abbreviations

ADA: 

adalimumab

BD: 

Behçet’s disease

CNS: 

central nervous system

GI: 

gastrointestinal

GWAS: 

genome-wide association studies

IBD: 

inflammatory bowel disease

IFX: 

infliximab

ISG: 

International Study Group

NSAIDs: 

non-steroidal anti-inflammatory drugs

TNF: 

tumor necrosis factor

Declarations

Acknowledgements

We wish to thank Mr Tom Kiper for his critical review in preparing the manuscript.

Funding

Y Kirino is supported by grants from the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (Grant No. 26713036 and 15K15374), the Kanae Foundation for the Promotion of Medical Science, Takeda Science Foundation, and Yokohama Foundation for Advancement of Medical Science. R Yoshimi is supported by grants from the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (Grant No. 26461468) and Yokohama Foundation for Advancement of Medical Science. M Takeno is supported by grants from the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (Grant No. 26461469) and the Behçet’s Disease Research Committee, Research on Specific Disease of the Health Science Research, the Ministry of Health, Labor, and Welfare.

Authors’ contributions

Y Kirino conceived of the study, obtained data performed the statistical analysis, participated in its design and coordination, and wrote the manuscript; HI conceived of the study and obtained data; M Takeno conceived of the study, participated in its design and coordination, and wrote the manuscript; A Suda conceived of the study and obtained data from charts; KH obtained data and participated in analysis and interpretation of data; Y Kunishita obtained data and participated in analysis and interpretation of data; KT obtained data and participated in analysis and interpretation of data; M Tamura, obtained data and participated in analysis and interpretation of data; TW obtained data and participated in analysis and interpretation of data; YA obtained data and participated in analysis and interpretation of data; RY obtained data and participated in analysis and interpretation of data; TU obtained data and participated in analysis and interpretation of data; TY obtained data and participated in analysis and interpretation of data; A Sekiguchi obtained data and participated in analysis and interpretation of data; AI obtained data and participated in analysis and interpretation of data; SO obtained data and participated in analysis and interpretation of data; AU obtained data and participated in analysis and interpretation of data; TI obtained data and participated in analysis and interpretation of data; SN obtained data and participated in analysis and interpretation of data; YI participated in coordination of the study, obtained data, and participated in analysis and interpretation of data; HN participated in analysis and interpretation of data. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by Ethic Committee of Yokohama City University (A141127010). The study followed the Ethical Guidelines for Epidemiology Research, published by Japanese Ministry of Health, Labor, and Welfare. Data were collected from chart-records without informed consent, unless the patient refused explicitly (opt-out method).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine
(2)
Department of Rheumatology, Yokohama Minami Kyosai Hospital
(3)
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine
(4)
Yokosuka Center for Rheumatic Diseases, Yokosuka City Hospital
(5)
Center for Rheumatic Diseases, Yokohama City University Medical Center
(6)
Department of Rheumatology, National Hospital Organization Yokohama Medical Center
(7)
Department of Rheumatology, Chigasaki City Hospital
(8)
Department of Rheumatology, Yamato City Hospital
(9)
Department of Hematology and Rheumatology, Fujisawa City Hospital
(10)
Yokohama City University
(11)
Y-CURD study group

References

  1. Dalvi SR, Yildirim R, Yazici Y. Behcet's Syndrome. Drugs. 2012;72(17):2223–41.PubMedView ArticleGoogle Scholar
  2. Isogai E, Ohno S, Kotake S, Isogai H, Tsurumizu T, Fujii N, Yokota K, Syuto B, Yamaguchi M, Matsuda H, et al. Chemiluminescence of neutrophils from patients with Behcet's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol. 1990;35(1):43–8.PubMedView ArticleGoogle Scholar
  3. Sohn S, Lee ES, Bang D, Lee S. Behcet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol. 1998;8(1):21–3.PubMedGoogle Scholar
  4. Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Ugurlu S, Erer B, Abaci N, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A. 2013;110(20):8134–9.PubMedPubMed CentralView ArticleGoogle Scholar
  5. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313–23.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, Grassi A, Rampelli S, Silvestri E, et al. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269–76.PubMedView ArticleGoogle Scholar
  7. Wakabayashi T, Morimura Y, Miyamoto Y, Okada AA. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm. 2003;11(4):277–86.PubMedView ArticleGoogle Scholar
  8. Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90(2):125-132.Google Scholar
  9. Kim DY, Choi MJ, Cho S, Kim DW, Bang D. Changing clinical expression of Behcet disease in Korea during three decades (1983-2012): chronological analysis of 3674 hospital-based patients. Br J Dermatol. 2014;170(2):458–61.PubMedView ArticleGoogle Scholar
  10. Mizushima Y, Inaba G, Mimura Y. Guide for the diagnosis of Behçet’s disease. Japan: Report of Behçet’s Disease Research; 1987. p. 8–17.Google Scholar
  11. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335(8697):1078–80.Google Scholar
  12. Saadoun D, Wechsler B, Desseaux K, Le Thi HD, Amoura Z, Resche-Rigon M, Cacoub P. Mortality in Behcet's disease. Arthritis Rheum. 2010;62(9):2806–12.PubMedView ArticleGoogle Scholar
  13. Bonitsis NG, Luong Nguyen LB, LaValley MP, Papoutsis N, Altenburg A, Kotter I, Micheli C, Maldini C, Mahr A, Zouboulis CC. Gender-specific differences in Adamantiades-Behcet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology (Oxford). 2015;54(1):121–33.View ArticleGoogle Scholar
  14. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887–900.View ArticleGoogle Scholar
  15. Ishigatsubo Y, Takeno M. Overview. In: Ishigatsubo Y, editor. Behçet's Disease: From Genetics to Therapies. Tokyo: Springer Japan; 2015. p. 1–20.Google Scholar
  16. Ideguchi H, Suda A, Takeno M, Miyagi R, Ueda A, Ohno S, Ishigatsubo Y. Gastrointestinal manifestations of Behcet's disease in Japan: a study of 43 patients. Rheumatol Int. 2014;34(6):851–6.PubMedView ArticleGoogle Scholar
  17. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, Senocak M, Yazici H. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–74.PubMedView ArticleGoogle Scholar
  18. Kitamei H, Kitaichi N, Namba K, Kotake S, Goda C, Kitamura M, Miyazaki A, Ohno S. Clinical features of intraocular inflammation in Hokkaido, Japan. Acta Ophthalmol. 2009;87(4):424–8.PubMedView ArticleGoogle Scholar
  19. Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, Lhote F, Ramanoelina J, Coste J, Guillevin L. Population-based prevalence study of Behcet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9.PubMedView ArticleGoogle Scholar
  20. Hirohata T, Kuratsune M, Nomura A, Jimi S. Prevalence of Behcet's syndrome in Hawaii with particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975;34(7):244–6.PubMedGoogle Scholar
  21. Zouboulis CC, Kotter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, Keitel W, Stadler R, Wollina U, Proksch E, et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. Yonsei Med J. 1997;38(6):411–22.PubMedView ArticleGoogle Scholar
  22. Lewis KA, Graham EM, Stanford MR. Systematic review of ethnic variation in the phenotype of Behcet's disease. Scand J Rheumatol. 2007;36(1):1–6.PubMedView ArticleGoogle Scholar
  23. Mumcu G, Inanc N, Yavuz S, Direskeneli H. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet's disease. Clin Exp Rheumatol. 2007;25(4 Suppl 45):S27–33.PubMedGoogle Scholar
  24. Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S2–5.PubMedGoogle Scholar
  25. Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behcet's syndrome. Infect Immun. 1991;59(4):1434–41.PubMedPubMed CentralGoogle Scholar
  26. Rizvi SW, McGrath Jr H. The therapeutic effect of cigarette smoking on oral/genital aphthosis and other manifestations of Behcet's disease. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S77–8.PubMedGoogle Scholar
  27. Catrina AI, Joshua V, Klareskog L, Malmstrom V. Mechanisms involved in triggering rheumatoid arthritis. Immunol Rev. 2016;269(1):162–74.PubMedView ArticleGoogle Scholar
  28. Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Behcet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol. 1988;15(6):1029–30.PubMedGoogle Scholar
  29. Choi SM, Choi YJ, Kim JT, Lee SH, Park MS, Kim BC, Kim MK, Cho KH. A case of recurrent neuro-Behcet's disease after tooth extraction. J Korean Med Sci. 2010;25(1):185–7.PubMedView ArticleGoogle Scholar
  30. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet. 2010;42(8):698–702.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, Ito N, Kera J, Okada E, Yatsu K, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMedView ArticleGoogle Scholar
  32. Cheon JH, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, Kim JS, Kim YS, Choi CH, Ye BD, et al. Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104(10):2492–9.PubMedView ArticleGoogle Scholar
  33. Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr. 1996;63(5):741–5.PubMedGoogle Scholar
  34. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol. 2009;44(7):659–65.PubMedView ArticleGoogle Scholar
  35. Magro-Checa C, Salvatierra J, Rosales-Alexander JL, Orgaz-Molina J, Raya-Alvarez E. Life-threatening vasculo-Behcet following discontinuation of infliximab after three years of complete remission. Clin Exp Rheumatol. 2013;31(3 Suppl 77):96–8.PubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement